alternative and complementary medicine to solve these problems.
Rhus verniciflua Stokes (RVS) of the Anacardiaceae family, commonly known as the lacquer tree, was a traditional herbal medicine for various stomach diseases including cancer in Korea and China. 4, 5 Owing to a property of breaking up blood stasis and purging hardness based on traditional medicine theory, it could be a drug against malignant tumors. 6 Recently, flavonoids from RVS have been experimentally proven to have apoptotic activities in human cancer cell lines. 7, 8 Therefore, we manufactured a standard extract from RVS for the purpose of prolonging survival and improving the quality of life in patients with only palliative therapy available. Our integrative cancer clinic, composed of oncologists and oriental medicine doctors, was founded in June 2006, and RVS extract was prescribed as complementary treatment for all cancer patients refractory to conventional chemotherapy. Practically, we confirmed the anticancer effect of RVS on tumor cells in some cases without side effects. 9 In this study, we tried to investigate the clinical feasibility of the standardized RVS extract in complementary treatment of mCRC. C olorectal cancer is a lifestyle-related disease, which increases sharply and is now ranked forth in incidence and deaths from cancer in the republic of Korea. 1 Over the past 10 years, new chemotherapeutic agents such as irinotecan and oxaliplatin, and molecularly targeted agents including bevacizumab and cetuximab, have prolonged survival for patients with metastatic colorectal cancer (mCRC). Yet, despite these advances, nearly all patients with mCRC will succumb to their disease within 2 years. 2 The toxicities and drug resistance to chemotherapy still remain challenging problems because newer or more intensive regimens also have higher toxicity. 3 Therefore, there is much need for Background. To investigate the clinical feasibility of the standardized Rhus verniciflua Stokes (RVS) extract for the metastatic colorectal cancer (mCRC), experimentally proven to have anticancer activities. Patients and Methods. From July 2006 to November 2007, patients with conventional chemotherapy refractory mCRC were checked. After fulfilling inclusion/exclusion criteria, 36 patients were eligible for the final analysis. Overall survival and adverse events of patients treated with RVS in the aftercare period were determined. Results. On October 21, 2008, a total of 26 patients died while the remaining 10 patients were alive with evidence of disease. The median RVS administration period was 2.7 months (95% confidence interval, 1.9-3.5). The median overall survival for the entire population was 10.9 months (95% confidence interval, 5.6-16.1) and 1-year survival rate was 44.4%, which is compatible with external controls. By survival analysis using Cox proportional hazards model, the performance status and the prior chemotherapy regimen number significantly affected overall survival. Adverse reactions to the RVS treatment were mostly mild and selflimiting. Conclusion. Complementary treatment with the standardized RVS extract might be beneficial for patients with mCRC, since it positively affected overall survival without significant side effects. This study suggests that RVS could be a natural anticancer agent candidate for the treatment of colorectal adenocarcinoma.
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Patients and Methods

Eligibility
From July 2006 to November 2007, patients who fulfilled the following eligibility criteria were enrolled in this study: (1) historically confirmed metastatic colorectal adenocarcinoma; (2) at least 1 prior palliative chemotherapy regimen; (3) progression of radiological finding during or after chemotherapy according to response evaluation criteria in solid tumors; (4) performance status of 0 to 3 according to the Eastern Cooperative Oncology Group (ECOG) scale; (5) adequate bone marrow (leukocyte count ≥ 4.0 × 10 9 cells/l and platelet count ≥ 150 × 10 9 cells/l), hepatic (total bilirubin level ≤ 1.5 mg/dl), and renal function (serum creatinine level ≤ 1.5 mg/dl); and (6) more than 1 day of the standardized RVS extract administration. Exclusion criteria included the following: (1) prior history of taking herbal medicine including RVS;
(2) neurologic deficit such as dementia and epilepsy;
(3) pregnant state; or (4) life expectancy below 30 days. All patients signed written informed consent approved by the Institutional Review Board of the East-West Neo Medical Center (Seoul, Republic of Korea).
Standardized Extract of RVS and Treatment Course
The clinical application of RVS has been limited because an allergenic component, urushiol, causes severe contact dermatitis in sensitive individuals. Urushiol, a mixture of several derivatives of catechol, should be removed from RVS for pharmaceutical uses. A standardized extract of urushiol-free RVS was manufactured as follows.
10-year-old RVS stalks, including barks grown in Wonju, Republic of Korea, were processed to sawdust. They were subjected to an urushiol removal process by roasting them in an iron pot at 240°C for 50 minutes and extracted with a 10-fold volume of water at 90°C to 95°C for 6 hours (Korean patent No. 0504160). After filtration and lyophilization, the final product, aqueous RVS extract, was a dark brown powder. A component analysis method using high performance liquid chromatography showed that the RVS extract contained fustin, fisetin, sulfuretin, and butein, among others. The quality of the RVS extract was tested and controlled according to the quality standards of the Korea Food and Drug Administration and our hospital's standards (fustin > 13.0%, fisetin > 7.0%, urushiol not detected). Daily orally administration with 2 or 3 capsules containing 450 mg of RVS extract was prescribed.
Evaluation and Statistical Analysis
The primary end point was overall survival (OS) in the intent-to-treat analysis. OS was defined as the period from the date of starting RVS treatment until death from any cause. We verified the time of death by using data officially recorded by the Korean National Health Insurance on October 21, 2008. Survival curves were estimated using the Kaplan-Meier method. Safety was assessed in terms of toxicity and evaluated as grades 1 to 4 based on the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
To assess the relative significance of potential prognostic factors, we performed univariate and multivariate analyses using the log-rank test and the Cox proportional hazards models, respectively. A P value < .05 was considered statistically significant, and all analyses were performed using SPSS 12.0 for Windows.
Results
Patient Characteristics
A total of 36 consecutive patients acceptable for our eligibility criteria were selected from 69 metastatic colorectal cancer patients who visited the Integrative Cancer Center, East-West Neo Medical Center (Seoul, Republic of Korea).
The main characteristics of our patients' population are summarized in Table 1 . The median age was 51.5 years (range, 30-76 years). A total of 34 patients (94.4%) had undergone surgical resection of their primary tumor and 7 patients (19.4%) had received radiotherapy. Before starting RVS treatment, 15 patients (41.7%) had received 1 prior chemotherapy regimen and 21 patients (58.3%) had received 2 or more chemotherapy regimens. All of them had progressive disease during or after prior chemotherapy.
A total of 16 patients (44.4%) chose our RVS treatment as the complementary therapy with conventional treatment including chemotherapy or radiotherapy, while 15 patients (41.7%) visited us for alternative therapy after chemotherapy failure or refusal.
Treatment Outcomes
At the time of the analysis, 26 patients had expired while the remaining 10 patients were alive with evidence of disease. The median OS for the entire population was 10.9 months (95% confidence interval, 5.6-16.1), and the estimated 1-year survival rate was 44.4% (Figure 1 ). Patients received RVS treatment for 2.7 months (95% confidence interval, 1.9-3.5), of whom 11 patients received it for under 60 days and 25 patients for over 60 days. During RVS treatment, 15 patients (41.7%) received chemotherapy concurrently.
By univariate and multivariate analyses, the performance status, as well as the number of prior chemotherapy regimen, were significantly independent prognostic factors for OS ( Table 2 ). The median OS of the first-line failure group and the second-line or more failure group was 14.6 months (95% confidence interval, 9.0-20.1) and 8.1 months (95% confidence interval, 5.9-10.3) respectively ( Figure 2 ). The concurrent chemotherapy or the duration of RVS treatment did not significantly affect the OS, while patients who were administered RVS for more than 60 days survived longer than the others (12.5 months vs 5.6 months; Figure 3 ).
Safety and Toxicity
While hematologic toxicity related with RVS treatment was not observed, nonhematologic adverse effects were reported. Mild pruritus and dyspepsia were observed respectively in 2 patients with the toxicity grade 1, and symptoms diminished after reducing dosage of RVS. No patients had to discontinue treatment because of adverse events of RVS. Specific drug interactions between RVS and concurrent chemotherapy agents were not reported in 15 patients (Table 3 ).
Discussion
We evaluated the clinical feasibility of RVS as an alternative choice for patients with mCRC showing refractory to conventional chemotherapy. The efficacy was evaluated only by OS and not by any endpoints such as time to progression, the surrogate of OS. Progression parameter could not be exactly detected and would give biased data, because our participants were mostly inclined to refuse further evaluation, and the duration of follow-up checks was various among cases. 10 The median OS for the entire group of 36 patients was 10.9 months (95% confidence interval, 5.6-16.1), and the estimated 1-year survival rate was 44.4%, showing comparable with other clinical studies about second-line or third-line chemotherapy for mCRC. Our patients could be classified into 2 groups: 15 patients (41.7%) had failed 1 prior chemotherapy regimen and 21 patients (58.3%) had failed 2 or more chemotherapy regimens (median, 3.0) before starting RVS treatment. Therefore, the RVS treatment could be considered as second-line or fourth-line treatment, respectively in each group. It was recently reported that the median OS was 11.9 months with capecitabine plus oxaliplatin (XELOX) and 12.5 months with 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in patients with mCRC after prior irinotecan-based chemotherapy. 11 The median OS of FOLFOX-4 and FOLFOX-4 plus bevacizumab, as second-line chemotherapy for advanced colorectal cancer, were reported to be 10.8 and 13.0 months, respectively. 12 By comparing our survival outcomes (14.6 months; 95% confidence interval, 9.0-20.1) in second-line RVS group (N = 15) with external controls, the RVS treatment appeared beneficial to the survival of the patients with mCRC who failed prior first-line chemotherapy. In the fourth-line RVS group (N = 21), the median OS was 8.1 months (95% confidence interval, 5.9-10.3), which is compatible with other third-line therapy reports. 13 Two prognostic factors, performance status and number of prior chemotherapy regimens, are closely associated with OS by both univariate and multivariate analysis (P < .05).
Other factors, such as RVS administration duration, also influenced the median OS, but were not significant. Adverse events related to RVS were minor compared to chemotherapy as cytotoxic agents. Only 2 cases reported nonhematologic toxicities such as pruritus and dyspepsia. The toxicity grade was very mild and manageable. Specific drug interaction with chemotherapy was not observed, though 15 cases are few to decide the safety on concurrent chemotherapy.
The aqueous extract of urushiol-free RVS was experimentally shown to have antitumor properties in carcinoma of breast and uterine cervix in vitro and to suppress tumor volume in a xenograft mouse model system, using A549 nonsmall cell lung cancer and Lewis lung cancer cells in vivo, through inhibiting the proliferation and migratory activity of vascular endothelial growth factor. 14, 15 A purified flavonoid fraction prepared from RVS was also found to have effective antiproliferative and apoptotic activities on various tumor cell lines including human lymphoma, breast cancer, osteosarcoma, and transformed hepatoma cells. 4, 5, 7, 8 This anticancer mechanism was suggested since an ethanol extract of RVS induces G1-cell cycle arrest and apoptosis in human gastric cancer cells, via caspase activation followed by mitochondrial death and the release of cytochrome c from the mitochondrial intermembrane space. 16, 17 However, it was not observed in normal cells.
As it affects cancer cells in different ways with conventional chemotherapy agents, synergistic effect could be predictable. Recently, RVS was shown to potentiate cisplatin-induced antitumor activity in CT-26 murine colon carcinoma bearing mice, and to protect against cisplatininduced cytotoxicity. 18 In conclusion, this study provides promising outcomes that the RVS treatment might prolong the OS in colorectal cancer patients refractory to conventional chemotherapy without significant side effects. This result suggests that RVS could be a natural anticancer agent candidate for the treatment of colorectal adenocarcinoma. More controlled clinical trials, with large populations in multicenter trials, would be necessary to evaluate its efficacy and safety. 
